ABSTRACT
Objetivo: Analisar a influência da pandemia da COVID-19 na execução dos exames de rastreamento e diagnóstico dos cânceres de próstata, mama e colo uterino na população brasileira. Métodos: Estudo analítico transversal e quantitativo com levantamento do número desses exames realizados pelo SUS (Sistema Único de Saúde). Os dados foram extraídos do Datasus nos períodos de pré-pandemia (março/2019 a fevereiro/2020) e pandemia (março/2020 a fevereiro/2021). Foram extraídos os números de exames realizados mês a mês e comparados os períodos pré-pandemia com o de pandemia. Foi realizada uma análise estatística descritiva, e as médias mensais de exames realizados nos dois períodos foram comparadas usando o teste t de Student. Resultados: Na comparação entre os períodos pré-pandemia e de pandemia, houve diminuição de média de 45,2% no número de exames citopatológicos, (194.978 exames por mês a menos; p < 0,00001), de 44,4% nos exames de mamografia (142.015 mamografias a menos por mês; p < 0,00001) e de 24,4% nos exames de antígeno prostático específico (PSA) (148.815 exames a menos por mês; p = 0,0012). Conclusão: A influência da pandemia gerou uma diminuição considerável no número de exames de rastreamento, mamografia, dosagem de PSA e citopatológico, o que deverá se traduzir em aumento nos casos de doença avançada, com graves consequências negativas para os pacientes e para o sistema de saúde.
Objective: To analyze the impact of COVID-19 pandemic on the number of screening and diagnostic cancer tests performed for prostate, breast and cervical cancer in the Brazilian population. Methods: This was a transversal analytical and quantitative study on the number of screening and diagnostic cancer tests performed in the public Brazilian health care system SUS (Sistema Único de Saúde). Data were collected from the Datasus (online SUS database) during pre-pandemic (March/2019 to February/2020) and pandemic periods (March/2020 to February/2021). We obtained the number of tests performed monthly for each of the tests and compared the two periods. Descriptive statistics were employed and the monthly average number of tests performed in each period were compared using the T Student test. Results: Comparing the pre-pandemic levels with pandemic levels, we found that there was a 45.2% decrease in the number of Papanicolaou (PAP smear) tests (194,978 less exams per month, p < 0,00001), 44.4% decrease in mammograms (142,015 less tests per month, p < 0,00001), and a reduction of 24.4% in the number of prostate specific antigen (PSA) tests per month (minus 148,815 exams performed, p < 0.0012). Conclusion: There was a statistically significant reduction in the number of screening/diagnostic mammograms, PAP smears and PSA performed during the pandemic period, compared to the period before COVID-19. This reduction may result in an increase in the number of cases diagnosed at an advanced stage, with grave consequences for the patients and for the sustainability of the healthcare system.
Subject(s)
Prostatic Neoplasms , Breast Neoplasms , Uterine Cervical Neoplasms , COVID-19ABSTRACT
This case report describes a benign breast tumor, more specifically, an angiolipoma, in a 17-year-old female patient who presented with a nodule in the left breast, painful to palpation. The nodule is at an atypical breast site and has few records in the literature, which were considered in this description that aims at identifying the main histological, ultrasound, mammographic and immunohistochemical characteristics of breast angiolipoma; besides informing other professionals about the possible angiolipoma diagnosis when considering a benign breast tumor, despite its rare occurrence.
ABSTRACT
The intracystic papillary carcinoma (IPC) is one of the rarest types of breast cancer, mainly in men, representing less than 1% of the malignant diseases in the male sex. It is frequently associated with the ductal carcinoma in situ (DCIS), but there are also other forms such as the pure and the invasive ones. The male population breast cancer diagnosis is late and, therefore, it has a worse prognosis. The diagnosis is given by imaging tests and anatomopathological studies. The treatment consists of excisional tumor therapy, which can be carried out conservatively or through mastectomy, with or without adjuvant therapy.